Edwards Lifesciences Company Insiders
EW Stock | USD 76.79 0.23 0.30% |
Slightly above 83 percent of Edwards Lifesciences' insiders are selling. The analysis of insiders' sentiment of trading Edwards Lifesciences Corp stock suggests that a fairly large number of insiders are terrified at this time. Edwards Lifesciences employs about 15.8 K people. The company is managed by 32 executives with a total tenure of roughly 181 years, averaging almost 5.0 years of service per executive, having 493.75 employees per reported executive.
Michael Mussallem Chairman Chairman of the Board, Chief Executive Officer |
Larry Wood President Corporate Vice President - Transcatheter Aortic Valve Replacement |
Insider Sentiment 17
Mostly Selling
Selling | Buying |
Latest Trades
2025-06-16 | Larry L Wood | Disposed 8950 @ 75.23 | View | ||
2025-06-02 | Donald E Bobo Jr | Disposed 2570 @ 77.4 | View | ||
2025-05-22 | Daveen Chopra | Disposed 1500 @ 75.08 | View | ||
2025-05-09 | Scott B Ullem | Disposed 11250 @ 74.4 | View | ||
2025-05-07 | Wayne Markowitz | Disposed 268 @ 75.08 | View | ||
2025-05-05 | Bernard J Zovighian | Disposed 5980 @ 74.91 | View | ||
2025-04-21 | Bruce Westerman | Disposed @ 69.23 | |||
2025-04-14 | Donald E Bobo Jr | Disposed 9500 @ 69.81 | View | ||
2025-04-08 | Robert Bresnahan, Jr. | Acquired @ 67.04 | |||
2025-04-07 | Jefferson Shreve | Acquired @ 69 | |||
2025-03-26 | Scott B Ullem | Disposed 11250 @ 70.87 | View | ||
2025-03-13 | Donald E Bobo Jr | Disposed 9500 @ 67.96 | View | ||
2025-03-10 | Bernard J Zovighian | Disposed 6164 @ 69.51 | View | ||
2025-03-03 | Bruce Westerman | Acquired @ 71.37 | |||
2025-02-28 | Scott B Ullem | Disposed 11250 @ 70.78 | View | ||
2025-02-14 | Steven R Loranger | Disposed 5739 @ 76.42 | View | ||
2025-02-13 | Donald E Bobo Jr | Disposed 6500 @ 75.75 | View |
Monitoring Edwards Lifesciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Edwards Lifesciences' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Edwards Lifesciences Corp. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Edwards Lifesciences' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. Edwards Lifesciences Management Team Effectiveness
The company has Return on Asset (ROA) of 0.0842 % which means that for every $100 of assets, it generated a profit of $0.0842. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1651 %, which means that it produced $0.1651 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Total Assets is likely to climb to about 13.7 B in 2025. Non Current Assets Total is likely to climb to about 7.1 B in 2025Net Income Applicable To Common Shares is likely to climb to about 1.8 B in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 548 M in 2025.
Edwards Lifesciences Workforce Comparison
Edwards Lifesciences Corp is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 87,317. Edwards Lifesciences retains roughly 15,800 in number of employees claiming about 18% of equities under Health Care industry.
The company has Net Profit Margin (PM) of 0.76 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.29 %, which signifies that for every $100 of sales, it has a net operating income of $0.29. Edwards Lifesciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edwards Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edwards Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Edwards Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edwards Lifesciences Notable Stakeholders
An Edwards Lifesciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Edwards Lifesciences often face trade-offs trying to please all of them. Edwards Lifesciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Edwards Lifesciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Mussallem | Chairman of the Board, Chief Executive Officer | Profile | |
Larry Wood | Corporate Vice President - Transcatheter Aortic Valve Replacement | Profile | |
Catherine Szyman | Corporate Vice President - Critical Care | Profile | |
Scott Ullem | Chief Financial Officer, Corporate Vice President | Profile | |
Huimin Wang | Corporate Vice President - Japan, Asia and Pacific | Profile | |
JeanLuc Lemercier | Corporate Vice President - EMEA (Europe, Middle East and Africa) | Profile | |
Bernard Zovighian | Corporate Vice President -Surgical Heart Valve Therapy | Profile | |
Donald Bobo | Corporate Vice President - Strategy and Corporate Development | Profile | |
Paul LaViolette | Independent Director | Profile | |
Leslie Heisz | Independent Director | Profile | |
Steven Loranger | Independent Director | Profile | |
Kieran Gallahue | Independent Director | Profile | |
Nicholas Valeriani | Independent Director | Profile | |
Angela Fuente | Director Engineering | Profile | |
Martha Marsh | Lead Independent Director | Profile | |
William Link | Independent Director | Profile | |
Ramona Sequeira | Independent Director | Profile | |
Mark Peterson | Corporate Counsel | Profile | |
Arnold Pinkston | Corporate Counsel | Profile | |
Arnold JD | Corporate Counsel | Profile | |
Heisz Stone | Independent Director | Profile | |
Mark Wilterding | Vice Relations | Profile | |
Annette Bruls | Canada, EMEA | Profile | |
MD FACC | Corporate Officer | Profile | |
Daveen Chopra | Corporate Vice President - Surgical Structural Heart | Profile | |
Christine McCauley | Corporate Resources | Profile | |
Gary Sorsher | Senior Compliance | Profile | |
Daniel Lippis | Greater Japan | Profile | |
Todd Brinton | Co Officer | Profile | |
Dirksen Lehman | Corporate Affairs | Profile | |
Finn Haley | Vice Development | Profile | |
Andrew Dahl | Senior Officer | Profile |
About Edwards Lifesciences Management Performance
The success or failure of an entity such as Edwards Lifesciences Corp often depends on how effective the management is. Edwards Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Edwards management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Edwards management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 15700 people.
Please note, the imprecision that can be found in Edwards Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edwards Lifesciences Corp. Check Edwards Lifesciences' Beneish M Score to see the likelihood of Edwards Lifesciences' management manipulating its earnings.
Edwards Lifesciences Workforce Analysis
Traditionally, organizations such as Edwards Lifesciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Edwards Lifesciences within its industry.Edwards Lifesciences Manpower Efficiency
Return on Edwards Lifesciences Manpower
Revenue Per Employee | 344.3K | |
Revenue Per Executive | 170M | |
Net Income Per Employee | 263.9K | |
Net Income Per Executive | 130.3M | |
Working Capital Per Employee | 302.5K | |
Working Capital Per Executive | 149.4M |
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.